Lupin Limited (LUPIN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lupin Limited (LUPIN) has a cash flow conversion efficiency ratio of 0.147x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs29.03 Billion ≈ $313.93 Million USD) by net assets (Rs197.28 Billion ≈ $2.13 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lupin Limited - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Lupin Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Lupin Limited for a breakdown of total debt and financial obligations.
Lupin Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lupin Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mowi ASA
OL:MOWI
|
0.199x |
|
Stanley Black & Decker Inc
NYSE:SWK
|
0.106x |
|
Healthpeak Properties Inc
NYSE:DOC
|
0.036x |
|
Washington H Soul Pattinson & Company Ltd
AU:SOL
|
-0.041x |
|
Metso Oyj
HE:METSO
|
0.054x |
|
China Development Financial Holding Corp
TW:2883
|
-0.072x |
|
Hunan Yuneng New Energy Battery Material Co. Ltd. A
SHE:301358
|
N/A |
|
BorgWarner Inc
NYSE:BWA
|
0.110x |
Annual Cash Flow Conversion Efficiency for Lupin Limited (2004–2025)
The table below shows the annual cash flow conversion efficiency of Lupin Limited from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Lupin Limited.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs172.94 Billion ≈ $1.87 Billion |
Rs30.00 Billion ≈ $324.43 Million |
0.173x | -31.66% |
| 2024-03-31 | Rs143.73 Billion ≈ $1.55 Billion |
Rs36.48 Billion ≈ $394.56 Million |
0.254x | +67.83% |
| 2023-03-31 | Rs125.43 Billion ≈ $1.36 Billion |
Rs18.97 Billion ≈ $205.15 Million |
0.151x | +403.24% |
| 2022-03-31 | Rs122.22 Billion ≈ $1.32 Billion |
Rs3.67 Billion ≈ $39.72 Million |
0.030x | -77.14% |
| 2021-03-31 | Rs138.58 Billion ≈ $1.50 Billion |
Rs18.22 Billion ≈ $197.02 Million |
0.131x | +12.60% |
| 2020-03-31 | Rs125.81 Billion ≈ $1.36 Billion |
Rs14.69 Billion ≈ $158.85 Million |
0.117x | -3.37% |
| 2019-03-31 | Rs137.89 Billion ≈ $1.49 Billion |
Rs16.66 Billion ≈ $180.17 Million |
0.121x | -6.05% |
| 2018-03-31 | Rs136.17 Billion ≈ $1.47 Billion |
Rs17.51 Billion ≈ $189.38 Million |
0.129x | -57.69% |
| 2017-03-31 | Rs135.32 Billion ≈ $1.46 Billion |
Rs41.14 Billion ≈ $444.86 Million |
0.304x | +1022.36% |
| 2016-03-31 | Rs111.95 Billion ≈ $1.21 Billion |
Rs-3.69 Billion ≈ $-39.90 Million |
-0.033x | -110.73% |
| 2015-03-31 | Rs88.98 Billion ≈ $962.30 Million |
Rs27.33 Billion ≈ $295.57 Million |
0.307x | +7.27% |
| 2014-03-31 | Rs69.99 Billion ≈ $756.86 Million |
Rs20.04 Billion ≈ $216.72 Million |
0.286x | +20.48% |
| 2013-03-31 | Rs52.64 Billion ≈ $569.24 Million |
Rs12.51 Billion ≈ $135.29 Million |
0.238x | +73.36% |
| 2012-03-31 | Rs40.85 Billion ≈ $441.80 Million |
Rs5.60 Billion ≈ $60.57 Million |
0.137x | -42.67% |
| 2011-03-31 | Rs33.33 Billion ≈ $360.41 Million |
Rs7.97 Billion ≈ $86.18 Million |
0.239x | -8.32% |
| 2010-03-31 | Rs25.93 Billion ≈ $280.46 Million |
Rs6.76 Billion ≈ $73.15 Million |
0.261x | -20.06% |
| 2009-03-31 | Rs14.39 Billion ≈ $155.63 Million |
Rs4.70 Billion ≈ $50.78 Million |
0.326x | +62.70% |
| 2008-03-31 | Rs12.89 Billion ≈ $139.41 Million |
Rs2.59 Billion ≈ $27.96 Million |
0.201x | -1.57% |
| 2007-03-31 | Rs8.73 Billion ≈ $94.45 Million |
Rs1.78 Billion ≈ $19.24 Million |
0.204x | -8.77% |
| 2006-03-31 | Rs5.89 Billion ≈ $63.68 Million |
Rs1.32 Billion ≈ $14.22 Million |
0.223x | +18.37% |
| 2005-03-31 | Rs4.91 Billion ≈ $53.05 Million |
Rs925.60 Million ≈ $10.01 Million |
0.189x | -79.18% |
| 2004-03-31 | Rs4.32 Billion ≈ $46.67 Million |
Rs3.91 Billion ≈ $42.29 Million |
0.906x | -- |
About Lupin Limited
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutica… Read more